HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20170283494A1
SERIAL NO

15621950

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MITSUBISHI TANABE PHARMA CORPORATIONOSAKA-SHI OSAKA 541-8505

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fujino, Yasuhiro Osaka, JP 10 116
Ochi, Hiroshi Osaka, JP 55 511
Yoshikawa, Tsutomu Osaka, JP 43 492

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation